Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN22 | Q9Y2R2 | 15/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | PTPN12 | Q05209 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509270 | 0.93 | BCAT1 (0.50) | PTPN22PTPN1PTPN12NPC1LMNA | |
| SCHEMBL6510460 | 0.87 | PTPN22 (0.50) | PTPN22NPC1LMNACLK1RAB9A | |
| SCHEMBL6509586 | 0.81 | RAB9A (0.44) | PTPN22NPC1LMNACLK1RAB9A | |
| SCHEMBL6509900 | 0.77 | HTT (0.49) | LMNAMAPTKDM4EMEN1ALOX12 | |
| SCHEMBL6509957 | 0.74 | MMP2 (0.49) | PTPN22PTPN1PTPN12 | |
| SCHEMBL31353100 | 0.73 | PTPN22 (1.00) | PTPN22PTPN1PTPN12 | |
| SCHEMBL6507327 | 0.72 | ALDH1A1 (0.42) | NPC1LMNACLK1RAB9AMAPT | |
| SCHEMBL22587847 | 0.71 | PTGER4 (0.48) | PTPN22NPC1LMNACLK1RAB9A | |
| SCHEMBL31353106 | 0.71 | PTPN22 (1.00) | PTPN22PTPN1PTPN12 | |
| SCHEMBL31353126 | 0.70 | PTPN22 (0.77) | PTPN22PTPN1PTPN12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | claimed |
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137234-A1 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC11 | PTPN22 3254/4885PTPN1 4077/4885PTPN12 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.